SUBSCRIBERS

Threat to Advair from cheap generics greets GSK's new CEO

Published Tue, Feb 7, 2017 · 09:50 PM

London

EMMA Walmsley, GlaxoSmithKline's incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.

Just four days before she moves into the top job on April 1, US regulators could approve the first substitutable generic version of GSK's inhaled lung drug Advair, which has raked in more than a US$1 billion in sales every year since 2001.

Ms Walmsley is expected to formally present her …

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes

Consumer & Healthcare

Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself

Companies & Markets

Threat to Advair from cheap generics greets GSK's new CEO

Consumer & Healthcare

Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece

Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom

Swiss watch exports plunge as China and Hong Kong demand dries up

Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO

Billionaires selling cheap stuff get richer from inflation pain

Amazon to push cashierless shopping tech into more third-party stores, while backing off itself

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

SECTIONS

LIFESTYLE

Follow BT